Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series

SEMERCİ SÖZÜER, ZEYNEP BENGİ; TAŞKIRAN, Sarper; TUFAN, ALİ EVREN

Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series

Ali Evren TUFAN, (Abant İzzet Baysal Üniversitesi, Tıp Fakültesi, Çocuk ve Ergen Psikiyatrisi Anabilim Dalı, Bolu, Türkiye)

ZEYNEP BENGİ SEMERCİ SÖZÜER, (Bengi Semerci Enstitüsü, İstanbul, Türkiye)

Sarper TAŞKIRAN (Muğla Sıtkı Koçman Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Muğla, Türkiye)

Klinik Psikofarmakoloji Bülteni

1 0

Yıl: 2016 Cilt: 26 Sayı: 2 Sayfa Aralığı: 181 - 185 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series

Öz:

Tic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/ severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.

Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Association AP. Diagnostic And Statistical Manual Of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision); 2000.
2. Association AP. Diagnostic and Statistical Manual of Mental Disorders: Dsm-5: Amer Psychiatric Pub Incorporated; 2013. 3. Rickards H, Cavanna AE, Worrall R. Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol 2012;16(4):361-4. [CrossRef]
4. Murphy TK, Lewin AB, Storch EA, Stock S. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry 2013;52(12):1341-59. [CrossRef]
5. Egolf A, Coffey BJ. Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs Today (Barc) 2014;50(2):159-79. [CrossRef]
6. Hartmann A, Worbe Y. Pharmacological treatment of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013;37(6):1157-61. [CrossRef]
7. Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Munchau A. Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology. 2013;68:143-9. [CrossRef]
8. Rizzo R, Gulisano M, Cali PV, Curatolo P. Tourette Syndrome and comorbid ADHD: current pharmacological treatment options. Eur J Paediatr Neurol 2013;17(5):421-8. [CrossRef]
9. Waldon K, Hill J, Termine C, Balottin U, Cavanna AE. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol 2013;26(4):265-73. [CrossRef]
10. Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006;21(7):447-53. [CrossRef]
11. Duane DD. Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol 2006;21(4):358. [CrossRef]
12. Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008;18(5):509-15. [CrossRef]
13. Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol 2009;19(6):623-33. [CrossRef]
14. Wenzel C, Kleimann A, Bokemeyer S, Muller-Vahl KR. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol 2012;32(4):548- 50. [CrossRef]
15. Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry 2013;74(8):e772-80. [CrossRef]
16. Neuner I, Nordt C, Schneider F, Kawohl W. Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 months. Hum Psychopharmacol 2012;27(4):364-9. [CrossRef]
17. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011;20(4):173-96. [CrossRef]
18. Piccinni A, Veltri A, Marazziti D, Moroni I, Dell'Osso L. Effectiveness of a clozapine-aripiprazole combination in Tourette syndrome and bipolar spectrum disorder. J Neuropsychiatry Clin Neurosci 2013;25(1):E45. [CrossRef]
19. Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 2011;32(6):1213-7. [CrossRef]
20. Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. The J Clin Psychiatry 2007;68(7):1088-93. [CrossRef]
21. Murphy TK, Mutch PJ, Reid JM, Edge PJ, Storch EA, Bengtson M, et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009;19(4):441-7. [CrossRef]

APA	TUFAN A, SEMERCİ SÖZÜER Z, TAŞKIRAN S (2016). Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. , 181 - 185.
Chicago	TUFAN ALİ EVREN,SEMERCİ SÖZÜER ZEYNEP BENGİ,TAŞKIRAN Sarper Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. (2016): 181 - 185.
MLA	TUFAN ALİ EVREN,SEMERCİ SÖZÜER ZEYNEP BENGİ,TAŞKIRAN Sarper Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. , 2016, ss.181 - 185.
AMA	TUFAN A,SEMERCİ SÖZÜER Z,TAŞKIRAN S Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. . 2016; 181 - 185.
Vancouver	TUFAN A,SEMERCİ SÖZÜER Z,TAŞKIRAN S Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. . 2016; 181 - 185.
IEEE	TUFAN A,SEMERCİ SÖZÜER Z,TAŞKIRAN S "Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series." , ss.181 - 185, 2016.
ISNAD	TUFAN, ALİ EVREN vd. "Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series". (2016), 181-185.

APA	TUFAN A, SEMERCİ SÖZÜER Z, TAŞKIRAN S (2016). Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. Klinik Psikofarmakoloji Bülteni, 26(2), 181 - 185.
Chicago	TUFAN ALİ EVREN,SEMERCİ SÖZÜER ZEYNEP BENGİ,TAŞKIRAN Sarper Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. Klinik Psikofarmakoloji Bülteni 26, no.2 (2016): 181 - 185.
MLA	TUFAN ALİ EVREN,SEMERCİ SÖZÜER ZEYNEP BENGİ,TAŞKIRAN Sarper Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. Klinik Psikofarmakoloji Bülteni, vol.26, no.2, 2016, ss.181 - 185.
AMA	TUFAN A,SEMERCİ SÖZÜER Z,TAŞKIRAN S Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. Klinik Psikofarmakoloji Bülteni. 2016; 26(2): 181 - 185.
Vancouver	TUFAN A,SEMERCİ SÖZÜER Z,TAŞKIRAN S Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series. Klinik Psikofarmakoloji Bülteni. 2016; 26(2): 181 - 185.
IEEE	TUFAN A,SEMERCİ SÖZÜER Z,TAŞKIRAN S "Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series." Klinik Psikofarmakoloji Bülteni, 26, ss.181 - 185, 2016.
ISNAD	TUFAN, ALİ EVREN vd. "Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series". Klinik Psikofarmakoloji Bülteni 26/2 (2016), 181-185.